Resource Summary Report

Generated by RRID on Jul 28, 2026

InVivoMab anti-mouse PD-L1 (B7-H1)

RRID:AB_10949073
Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0101, RRID:AB_10949073)

Antibody Information

URL: http://antibodyregistry.org/AB_10949073

Proper Citation: (Bio X Cell Cat# BE0101, RRID:AB_10949073)

Target Antigen: PD-L1 (B7-H1)

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow Cytometry, Immunofluorescence, Immunohistochemistry, in vivo Neutralization & Blocking, Western Blot, in vitro Organoids/Organ-on-Chip
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:TRUE

Antibody Name: InVivoMab anti-mouse PD-L1 (B7-H1)

Description: This monoclonal targets PD-L1 (B7-H1)

Target Organism: mouse

Clone ID: clone 10F.9G2™

Antibody ID: AB_10949073

Vendor: Bio X Cell

Catalog Number: BE0101

Alternative Catalog Numbers: BE0101-100MG, BE0101-25MG, BE0101-50MG, BE0101-1MG, BE0101-5MG

Record Creation Time: 20260114T193156+0000

Record Last Update: 20260706T190413+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:TRUE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for InVivoMab anti-mouse PD-L1 (B7-H1).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 160 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Guo W, et al. (2026) Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective niche. Cancer cell, 44(1), 94.

Li C, et al. (2025) Glutamate transporter SLC1A6 promotes resistance to immunotherapy in cancer. Cancer immunology, immunotherapy : CII, 74(8), 240.

Shao YY, et al. (2025) Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma. Biology direct, 20(1), 49.

Wang S, et al. (2025) ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy. Cell reports. Medicine, 6(9), 102336.

Valvo VM, et al. (2025) Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. Molecular cancer therapeutics, 24(6), 843.

Chen J, et al. (2025) Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer cell, 43(3), 361.

Mu H, et al. (2025) Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. Cell reports. Medicine, 6(3), 101977.

Zhang Y, et al. (2025) Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. Cancer cell, 43(3), 446.

Yu H, et al. (2025) UDP-GlcUA triggers PKR kinase activity to promote liquid-liquid phase separation of TOP2A and enhances radioimmunotherapy resistance. Molecular cell, 85(21), 3913.

Wang J, et al. (2025) The transcription factor ZEB2 mediates the antitumor efficacy of tumor-infiltrating lymphocytes in non-small cell lung cancer. Cell death & disease, 16(1), 806.

Zhang Y, et al. (2025) Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. Cell, 188(24), 6754.

Hua D, et al. (2025) The combination of Clostridium butyricum and Akkermansia muciniphila mitigates DSS-induced colitis and attenuates colitis-associated tumorigenesis by modulating gut microbiota and reducing CD8+ T cells in mice. mSystems, 10(2), e0156724.

Elder AM, et al. (2025) Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer. Cell reports, 44(5), 115676.

Chen D, et al. (2025) DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. Cancer cell, 43(9), 1758.

Phelps CM, et al. (2025) Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell.

Niu D, et al. (2025) Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. Cell reports. Medicine, 6(10), 102413.

He J, et al. (2025) Potentiating immunotherapy in "immune-cold" solid tumors through orchestrating T cell immunity via tumor-specific genetic engineering. Cell reports. Medicine, 6(12), 102510.

Liu ZY, et al. (2025) Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. Immunity, 58(6), 1572.

Nie H, et al. (2025) Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer research, 85(18), 3471.

Hirade K, et al. (2025) Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy. Cell reports. Medicine, 6(9), 102317.